Öz
Giriş: Koronavirüs hastalığı-2019 (COVID-19) pandemisinin başlangıcından bu yana, bilim adamları COVID-19’u tedavi etmek için pek çok ilaç üzerinde çalıştılar ve bunların hiçbiri kesin tedavi olarak kabul edilmedi. Favipiravir, replikasyon sürecine müdahale ederek vücudu virüsten etkili bir şekilde temizleyen ilaçlardan biridir. Bu çalışma, orta şiddette COVID-19’lu hastaları tedavi etmek için destekleyici ilaçlarla karşılaştırıldığında favipiravirin etkinliğini belirlemeyi amaçladı.
Gereç ve Yöntem: Bu randomize, açık etiketli, kontrollü klinik çalışmada, orta şiddette COVID-19’lu hastaları tedavi etmek için favipiravirin etkinliğini inceledik. Çalışma, Nisan-Eylül 2021 tarihleri arasında İran’ın Tahran kentindeki Labbafinejad Hastanesi’nde gerçekleştirildi. Uygun hastalar müdahale ve kontrol gruplarına 1:1 oranında atandı. Kontrol grubu destekleyici ilaç aldı. Destekleyici ilaçlara ek olarak, müdahale grubuna favipiravir verildi. Birincil sonlanım noktası, yedi günlük takip sırasında hastaneye yatış oranıydı. İkincil sonlanım noktaları ise hastaların semptomları, bulguları ve laboratuvar testleriydi.
Bulgular: Çalışmaya dahil edilen 78 hastadan 40’ı kontrol grubuna, 38’i müdahale grubuna alındı. Tedavinin başlangıcında solunum hızı müdahale grubunda daha yüksekti (p=0,001), ancak beşinci (p=0,001) ve yedinci (p<0,001) günlerde müdahale grubunda anlamlı olarak daha düşüktü. Ayrıca müdahale grubunda tedavinin başlangıcında oksijen satürasyonu daha düşüktü (p<0,001), ancak beşinci (p=0,016) ve yedinci (p<0,001) günlerde müdahale grubunda anlamlı olarak daha yüksekti. Bununla birlikte, favipiravir kullanımı hastaneye yatış oranı ile ilişkili değildi (p=0,200).
Sonuç: Orta şiddette COVID-19’lu hastalarda favipiravir, tek başına destekleyici ilaçlara kıyasla solunumsal göstergeleri iyileştirmektedir.
Anahtar Kelimeler: Antiviral ajanlar, COVID-19, favipiravir, SARS-CoV-2
Kaynakça
Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020;17:141.
Tehrani S, Khabiri N, Moradi H, Mosavat MS, Khabiri SS. Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality. Clin Nutr ESPEN. 2021;42:313-7.
Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, Agrawal M, Alexander A. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375.
Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. Jama. 2020;323:1239-42.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Ju L, Zhang J, Wang X. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021;12:683296.
Han YJ, Ren ZG, Li XX, Yan JL, Ma CY, Wu DD, Ji XY. Advances and challenges in the prevention and treatment of COVID-19. Int J Med Sci. 2020;17:1803-10.
Tu YF, Chien CS, Yarmishyn AA, Lin YY, Luo YH, Lin YT, Lai WY, Yang DM, Chou SJ, Yang YP, Wang ML, Chiou SH. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. Int J Mol Sci. 2020;21:2657.
McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C. Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res. 2020;157:104859.
Jean SS, Lee PI, Hsueh PR. Treatment options for COVID-19: The reality and challenges. J Microbiol Immunol Infect. 2020;53:436-43.
Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021;21:489.
Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med. 2020;383:1757-66.
Marra AR, Kobayashi T, Suzuki H, Alsuhaibani M, Tofaneto BM, Bariani LM, Auler MA, Salinas JL, Edmond MB, Doll M, Kutner JM, Pinho JRR, Rizzo LV, Miraglia JL, Schweizer ML. Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis. J Infect. 2022;84:297-310.
Tabriz University of Medical Sciences. Available from: https://treatment .tbzmed.ac.ir/Uploads/User/4734/1399/%D9%85%D8%B9%D8%A7 %D9%88%D 9%86%D8%AA%20 % D8%AF%D 8%B1%D9% 85%D8%A7 %D9%86/%D8% A7 %D8 %B9 %D8%A A%D8%A8%D8%A7%D8%B1%20 %D8%A8%D8%AE%D8%B4%DB%8C/%d9%86%d8% b3%d8%ae%d9%87%20%d9%86%d9%87%d9%85%20%d8%b1%d8%a7%d9%87%d9%86%d9%85% d8%a7%db%8c%20%d8%aa%d8%b4%d8%ae%db%8c%d8%b5%20%d9%88%20%d8 %af%d8%b1%d9%85.pdf
Alamer A, Alrashed AA, Alfaifi M, Alosaimi B, AlHassar F, Almutairi M, Howaidi J, Almutairi W, Mohzari Y, Sulaiman T, Al-Jedai A, Alajami HN, Alkharji F, Alsaeed A, Alali AH, Baredhwan AA, Abraham I, Almulhim AS. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis. Curr Med Res Opin. 2021;37:1085-97.
Shinkai M, Tsushima K, Tanaka S, Hagiwara E, Tarumoto N, Kawada I, Hirai Y, Fujiwara S, Komase Y, Saraya T, Koh H, Kagiyama N, Shimada M, Kanou D, Antoku S, Uchida Y, Tokue Y, Takamori M, Gon Y, Ie K, Yamazaki Y, Harada K, Miyao N, Naka T, Iwata M, Nakagawa A, Hiyama K, Ogawa Y, Shinoda M, Ota S, Hirouchi T, Terada J, Kawano S, Ogura T, Sakurai T, Matsumoto Y, Kunishima H, Kobayashi O, Iwata S. Efficacy and Safety of Favipiravir in Moderate COVID-19 Pneumonia Patients without Oxygen Therapy: A Randomized, Phase III Clinical Trial. Infect Dis Ther. 2021;10:2489-509.
Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, Kadam J, Wu W, Caracta CF, Tandon M. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021;103:62-71.
Ivashchenko AA, Dmitriev KA, Vostokova NV, Azarova VN, Blinow AA, Egorova AN, Gordeev IG, Ilin AP, Karapetian RN, Kravchenko DV, Lomakin NV, Merkulova EA, Papazova NA, Pavlikova EP, Savchuk NP, Simakina EN, Sitdekov TA, Smolyarchuk EA, Tikhomolova EG, Yakubova EV, Ivachtchenko AV. AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. Clin Infect Dis. 2021;73:531-4.
Szabo BG, Lenart KS, Petrik B, Gaspar Z, Kiss-Dala N, Szlavik J, Valyi-Nagy I, Lakatos B; Saint Ladislaus COVID-19 Collaborative. Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary. Geroscience. 2021;43:2205-13.
Lou Y, Liu L, Yao H, Hu X, Su J, Xu K, Luo R, Yang X, He L, Lu X, Zhao Q, Liang T, Qiu Y. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial. Eur J Pharm Sci. 2021;157:105631.
Al-Muhsen S, Al-Numair NS, Saheb Sharif-Askari N, Basamh R, Alyounes B, Jabaan A, Saheb Sharif-Askari F, Alosaimi MF, Alsohime F, Halwani R, Al-Saud H. Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia. Front Med (Lausanne). 2022;9:826247.
Solaymani-Dodaran M, Ghanei M, Bagheri M, Qazvini A, Vahedi E, Hassan Saadat S, Amin Setarehdan S, Ansarifar A, Biganeh H, Mohazzab A, Khalili D, Hosein Ghazale A, Reza Heidari M, Taheri A, Khoramdad M, Mahdi Asadi M, Nazemieh M, Varshochi M, Abbasian S, Bakhtiari A, Mosaed R, Hosseini-Shokouh SJ, Shahrokhi M, Yassin Z, Ali Zohal M, Qaraati M, Rastgoo N, Sami R, Javad Eslami M, Asghari A, Namazi M, Ziaie S, Jafari-Moghaddam R, Kalantari S, Memarian M, Khodadadi J, Hossein Afshari M, Momen-Heravi M, Behzadseresht N, Reza Mobayen A, Mozafari A, Movasaghi F, Haddadzadeh Shoushtari M, Moazen J. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia. Int Immunopharmacol. 2021;95:107522.
Chen C, Zhang Y, Huang J, Yin P, Cheng Z, Wu J, Chen S, Zhang Y, Chen B, Lu M, Luo Y, Ju L, Zhang J, Wang X. Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial. Front Pharmacol. 2021;12:683296.
Mortaz E, Bassir A, Dalil Roofchayee N, Dezfuli NK, Jamaati H, Tabarsi P, Moniri A, Rezaei M, Mehrian P, Varahram M, Marjani M, Mumby S, Adcock IM. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra. Int Immunopharmacol. 2021;93:107407.
Zhao H, Zhang C, Zhu Q, Chen X, Chen G, Sun W, Xiao Z, Du W, Yao J, Li G, Ji Y, Li N, Jiang Y, Wang Y, Zeng Q, Li W, Gong B, Chang X, Zhu F, Jiang X, Li J, Wu Z, Liu Y, Peng P, Wang G. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial. Int Immunopharmacol. 2021;97:107702.
Wang D, Li Z, Liu Y. An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health. 2020;13:1405-14.
Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, Patil S, Barkate H. Role of favipiravir in the treat-ment of COVID-19. Int J Infect Dis. 2021;102:501-8.
